Cyclin dependent Kinase News and Research

RSS

Tabula sapiens, most comprehensive human cell atlas

In a recent study published in the journal Science, researchers created an atlas termed the Tabula sapiens for over 400 distinct cell types of humans. Several aspects of human physiology were revealed by the atlas, such as how different types of cells splice genes differently.

16 May 2022

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

CDK6: a potential drug target for severe COVID-19

Researchers identify a methodology and workflow to repurpose drugs against the cyclin-dependent kinase 6 target gene of SARS-CoV-2.

27 Mar 2022

Clearing old, dysfunctional cells in fat alleviates diabetes

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from UConn Health report. The discovery could lead to new treatments for Type 2 diabetes and other metabolic diseases.

22 Nov 2021

Hollings Cancer Center researcher awarded NCI grant to pursue early investigator studies in leukemia

MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., was awarded a five-year $344,000 per year grant by the National Cancer Institute to pursue her early investigator studies in leukemia.

5 Oct 2021

City of Hope researchers identify how breast cancer cells acquire resistant traits

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer.

24 Jun 2021

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

Aging published "Cdkn1a transcript variant 2 is a marker of aging and cellular senescence" which reported that cellular senescence is a cell fate response characterized by a permanent cell cycle arrest driven primarily the by cell cycle inhibitor and tumor suppressor proteins p16Ink4a and p21Cip1/Waf1.

3 Jun 2021

Researcher from Hollings Cancer Center wins Melanoma Research Alliance grant

MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance.

29 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

Researchers examine circRNAs encoded by MERS-CoV, SARS-CoV-1 and SARS-CoV-2

New research published in Briefings in Bioinformaticsm has identified thousands of circRNAs in Betacoronaviruses, including MERS-CoV, SARS-CoV-1, and SARS-CoV-2, from the RNA-sequencing data of viral infections. These coronaviruses have a similar genomic structure with a diverse circRNA coding ability. Researchers have also systematically characterized circRNAs in coronaviruses, with regard to their size, sequence feature, expressions, genome, location preference, and functions. This opens the door to further explore and understand the mode of action of individual circRNAs in coronaviruses.

29 Mar 2021

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression

Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

13 Feb 2021

A brain enzyme plays an important role in waking up neural stem cells

Researchers studying an enzyme in fruit fly larvae have found that it plays an important role in waking up brain stem cells from their dormant 'quiescent' state, enabling them to proliferate and generate new neurons.

12 Feb 2021

New data shows abemaciclib continues to benefit high-risk, HR+, HER2-, early-stage breast cancer patients

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Novel insights on a common protein could have broad biomedical applications

A new University of Colorado Boulder-led study sheds light on a protein key to controlling how cells grow, proliferate and function and long implicated in tumor development.

4 Nov 2020

Study: Pleotropic drugs can have both favorable and unfavorable effects on cell growth, survival

The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.

17 Sep 2020

Study identifies phosphorylation-based biomarkers to guide cancer therapy

Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients.

28 Jul 2020

Ivy Center opens new clinical trial to evaluate experimental drug cocktail for glioblastoma

The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a new Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996.

27 May 2020

Researchers discover how CDK8 oncogene gets activated in healthy humans

Most cancers are caused by a large variety of factors that vary from one person to another. To unravel this complexity, genes that contribute to the development of a respective cancer must be identified. Such genes are called oncogenes. A good example of an oncogene is CDK8: Cyclin-dependent kinase 8.

28 Jan 2020

Study finds stress does whiten hair

In most cases, hair starts to gray in the thirties, and becomes pronounced in the fifties, at which time the head is typically crowned with a thatch of white, gray and perhaps some hair of the original color. A new study published January 2020 in the journal Nature, shows that this process is speeded up significantly by acute stress persisting over a period, or by severe trauma.

22 Jan 2020

Adding targeted therapy drug to standard treatment benefits aggressive breast cancer patients

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

29 Sep 2019